NASDAQ
Halozyme Therapeutics, Inc. (HALO) has a price/fcf ratio of 12.51x as of Monday, May 25, 2026. This represents a 35.90% decrease compared to its 12-month average of 19.52x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.
No price data available for this timeframe.